These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34359048)

  • 1. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
    McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
    J Neurosurg Pediatr; 2021 Oct; 28(4):371-379. PubMed ID: 34359048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
    Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
    J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
    Kulason KO; Schneider JR; Chakraborty S; Filippi CG; Pramanik B; Wong T; Fralin S; Tan K; Ray A; Alter RA; Ortiz R; Demopoulos A; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2018 May; 12(3):223-229. PubMed ID: 29790314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
    Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
    J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.
    Souweidane MM; Kramer K; Pandit-Taskar N; Zhou Z; Haque S; Zanzonico P; Carrasquillo JA; Lyashchenko SK; Thakur SB; Donzelli M; Turner RS; Lewis JS; Cheung NV; Larson SM; Dunkel IJ
    Lancet Oncol; 2018 Aug; 19(8):1040-1050. PubMed ID: 29914796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
    Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
    J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma.
    Su JM; Murray JC; McNall-Knapp RY; Bowers DC; Shah S; Adesina AM; Paulino AC; Jo E; Mo Q; Baxter PA; Blaney SM
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28283. PubMed ID: 32285998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
    Crotty EE; Leary SES; Geyer JR; Olson JM; Millard NE; Sato AA; Ermoian RP; Cole BL; Lockwood CM; Paulson VA; Browd SR; Ellenbogen RG; Hauptman JS; Lee A; Ojemann JG; Vitanza NA
    J Neurooncol; 2020 Jul; 148(3):607-617. PubMed ID: 32556862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
    Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
    World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.
    Anderson RC; Kennedy B; Yanes CL; Garvin J; Needle M; Canoll P; Feldstein NA; Bruce JN
    J Neurosurg Pediatr; 2013 Mar; 11(3):289-95. PubMed ID: 23240851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeat convection-enhanced delivery for diffuse intrinsic pontine glioma.
    Bander ED; Ramos AD; Wembacher-Schroeder E; Ivasyk I; Thomson R; Morgenstern PF; Souweidane MM
    J Neurosurg Pediatr; 2020 Dec; 26(6):661-666. PubMed ID: 32977309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
    El-Khouly FE; Veldhuijzen van Zanten SEM; Jansen MHA; Bakker DP; Sanchez Aliaga E; Hendrikse NH; Vandertop WP; van Vuurden DG; Kaspers GJL
    J Neurooncol; 2021 Jun; 153(2):263-271. PubMed ID: 33963476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the Blood-Brain Barrier to Target Diffuse Intrinsic Pontine Glioma: What's New?
    Lu VM; Power EA; Zhang L; Daniels DJ
    World Neurosurg; 2020 Jul; 139():618-619. PubMed ID: 32389870
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
    Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
    J Neurosurg Pediatr; 2019 Mar; 23(3):333-342. PubMed ID: 30544335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deformational changes after convection-enhanced delivery in the pediatric brainstem.
    Bander ED; Tizi K; Wembacher-Schroeder E; Thomson R; Donzelli M; Vasconcellos E; Souweidane MM
    Neurosurg Focus; 2020 Jan; 48(1):E3. PubMed ID: 31896089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
    Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
    J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
    Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report.
    Ivasyk I; Morgenstern PF; Wembacher-Schroeder E; Souweidane MM
    J Neurosurg Pediatr; 2017 Sep; 20(3):256-260. PubMed ID: 28686124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical tolerance of corticospinal tracts in convection-enhanced delivery to the brainstem.
    Morgenstern PF; Zhou Z; Wembacher-Schröder E; Cina V; Tsiouris AJ; Souweidane MM
    J Neurosurg; 2019 Dec; 131(6):1812-1818. PubMed ID: 30579270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.